FDA Warns Chinese Peptide Maker Harbin Jixianglong Over Relabeled Semaglutide API Shipped to the U.S.
On May 1, 2026, FDA issued a warning letter to Harbin Jixianglong Biotech Co., Ltd., a manufacturer of peptide APIs including GLP-1 receptor agonist APIs. FDA says the firm bought semaglutide API from suppliers not on its approved supplier list, repackaged and relabeled the batches naming itself as manufacturer, and changed manufacturing and retest dates "without appropriate supporting data" before the API was distributed to the U.S. The letter cites "CGMP/API/Adulterated and Misbranded Drugs" and references Import Alert 66-80, which covers GLP-1 API drugs offered for import.
What this meansA compounded GLP-1 is only as trustworthy as the API behind it — findings like these are why asking a pharmacy where its active ingredient comes from is a fair and important question.
Source: FDA original ↗